Atossa Therapeutics, Inc. ATOS
Set alert
At close
Pre-market · Nov 2, 8:15 AM ET
- YTD
- -75.48%
- 1 year
- -83.56%
- Open
- 2.25
- Prev close
- 2.23
- Mkt cap
- 21.66M
- Vol
- 32.90K
- Avg vol
- 70.85K
- EPS
- -4.45
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.15
- High
- 2.43
- Forward P/E
- -3.81
- Beta
- 1.23
- Short ratio
- 14.73
- Inst. own
- 28.16%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.31
- 200-d avg
- 1.39
- 1y target
- 6.00
5D chart
Signals (83)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 1:35 PM | 2 days ago |
| RSI: Oversold | Oct 30, 1:20 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 12:15 PM | 2 days ago |
| RSI: Oversold | Oct 30, 10:45 AM | 2 days ago |
| SMA: Bearish | Oct 30, 10:30 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 10:30 AM | 2 days ago |
| SMA: Bullish | Oct 30, 9:35 AM | 3 days ago |
| MACD: Buy Signal | Oct 30, 9:35 AM | 3 days ago |
| RSI: Overbought | Oct 30, 9:35 AM | 3 days ago |
| RSI: Oversold | Oct 29, 3:35 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:25 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 3:25 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:15 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:05 PM | 3 days ago |
| RSI: Oversold | Oct 29, 3:00 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:00 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 2:00 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:45 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:40 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:05 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:00 PM | 3 days ago |
| SMA: Bullish | Oct 29, 11:55 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 11:55 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 11:45 AM | 3 days ago |
| RSI: Oversold | Oct 29, 11:40 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 11:30 AM | 3 days ago |
| RSI: Oversold | Oct 29, 10:35 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:30 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:30 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:20 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 10:20 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:00 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:00 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 9:55 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:50 AM | 3 days ago |
| RSI: Oversold | Oct 29, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 3:30 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 3:30 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:15 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:10 PM | 4 days ago |
| RSI: Oversold | Oct 28, 2:30 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 1:15 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:40 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:20 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 9:45 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 5 days ago |
| RSI: Oversold | Oct 27, 3:40 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 3:35 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:10 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:45 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:45 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:40 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:10 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:05 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 1:05 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:00 PM | 5 days ago |
| RSI: Overbought | Oct 27, 12:45 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:00 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:00 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 12:00 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:45 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 11:10 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:25 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:10 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 10:10 AM | 5 days ago |
| RSI: Overbought | Oct 27, 9:35 AM | 6 days ago |
| SMA: Bullish | Oct 26, 3:30 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:30 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 3:05 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 2:50 PM | 6 days ago |
| RSI: Oversold | Oct 26, 2:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:30 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 2:25 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:20 PM | 6 days ago |
| RSI: Oversold | Oct 26, 1:35 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 12:35 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:20 PM | 6 days ago |
| SMA: Bullish | Oct 26, 11:55 AM | 6 days ago |
| RSI: Oversold | Oct 26, 11:50 AM | 6 days ago |
| SMA: Bullish | Oct 26, 10:50 AM | 6 days ago |
News
-
2 weeks ago benzinga.com
Atossa Therapeutics Confirms Shares To Begin Trading With One Stapled Contingent Value Right As Of Close Of Business On October 19
Under the terms of the Stapled Contingent Value Rights Agreement (the "CVR Agreement") with VStock Transfer, LLC, as rights agent, each share of Atossa common stock outstanding at the close of…
2 weeks ago prnewswire.com
Atossa Therapeutics Common Stock to Begin Trading with Stapled Contingent Value Rights After Close of Business Today
One CVR will attach to each outstanding share of Atossa common stock as of the close of business on October 19, 2026, and shares and CVRs will transfer together while stapled Shares issued after…
-
3 weeks ago benzinga.com
Atossa Therapeutics Inks Stapled Contingent Value Rights Agreement With VStock Transfer; Atossa Declares Dividend Of One Stapled CVR For Each Share Of Atossa Common Stock
Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines in oncology and other areas of significant unmet need,
3 weeks ago prnewswire.com
Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value
Board declares one stapled CVR for each share of Atossa common stock outstanding as of October 19, 2026 record date or issued thereafter CVRs entitle holders to 25% of net proceeds from monetization…
-
1 month ago benzinga.com
Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $25
Ascendiant Capital analyst Edward Woo maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and raises the price target from $24 to $25.
1 month ago prnewswire.com
Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher
Shareholders would receive one CVR for each ATOS share held as of the record date or issued thereafter CVRs would entitle holders to 25% of net proceeds from monetization of Atossa's first qualifying…
1 month ago prnewswire.com
Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging
Panel at Harvard University will explore translating evidence in diseases of aging into new therapeutics and regulatory pathways SEATTLE, Sept. 24, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc.…
-
2 months ago benzinga.com
Atossa Therapeutics Q2 EPS $(0.95) Beats $(1.02) Estimate
Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(0.95) per share which beat the analyst consensus estimate of $(1.02) by 6.86 percent. This is a 171.43 percent decrease over losses of…
2 months ago prnewswire.com
Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
SEATTLE, Aug. 7, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other…
-
3 months ago benzinga.com
Atossa Therapeutics Announces npj Breast Cancer Publication Highlighting Novel Endoxifen-Based Compounds In ESR1-Mutant Breast Cancer Models
Peer-reviewed preclinical study published in npj Breast Cancer identifies new chemical entities with activity in ESR1-mutant modelsFindings suggest potential for combination with abemaciclibSEATTLE,…
3 months ago prnewswire.com
Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer
Peer-reviewed preclinical study published in npj Breast Cancer identifies new chemical entities with activity in ESR1-mutant models Findings suggest potential for combination with abemaciclib…
-
3 months ago benzinga.com
Atossa Therapeutics Presents Mechanism-Driven (Z)-Endoxifen Data In McCune-Albright Syndrome At 2026 AACR Special Conference In Cancer Research
Preclinical Data Poster Highlights Dual Estrogen Receptor and PKC-β/AKT Pathway Modulation as a Potential Therapeutic Strategy for Estrogen-Driven Pathology in McCune-Albright syndromeSEATTLE, July…
3 months ago prnewswire.com
Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers
Preclinical Data Poster Highlights Dual Estrogen Receptor and PKC-β/AKT Pathway Modulation as a Potential Therapeutic Strategy for Estrogen-Driven Pathology in McCune-Albright syndrome SEATTLE, July…
-
3 months ago benzinga.com
Rodman & Renshaw Initiates Coverage On Atossa Therapeutics with Buy Rating, Announces Price Target of $12
Rodman & Renshaw analyst Michael G. King Jr. initiates coverage on Atossa Therapeutics (NASDAQ:ATOS) with a Buy rating and announces Price Target of $12.
4 months ago prnewswire.com
Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds
$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrants SEATTLE, June 12, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc.…
4 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
4 months ago benzinga.com
Crude Oil Edges Higher; Driven Brands Posts Upbeat Earnings
US stocks rise with Nasdaq up 150 points. Dow up 0.54%, Nasdaq up 0.63%, S&P 500 up 0.26%. Industrials and Enliven Therapeutics lead gains. Dana Inc and Oracle Corp down. Oil up 0.7%, gold down 0.7%.…
4 months ago benzinga.com
Dow Jumps Over 250 Points; US Initial Jobless Claims Rise
US stocks up, Dow gains 250 pts. Dow up 0.58% while NASDAQ up 0.67%. Materials shares jump 1.5%, communication services down 1.3%. Jobless claims up.
-
4 months ago benzinga.com
Atossa Therapeutics Enters Securities Purchase Agreement With Institutional Investors For 1,363,638 Shares
Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need,…
4 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
4 months ago prnewswire.com
Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds
$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrants SEATTLE, June 11, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc.…
5 months ago prnewswire.com
Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial
Preclinical Data Abstract Demonstrates Robust Estrogen Receptor (ER) Inhibition in ESR1-Mutant Breast Cancer Models at Clinically Relevant Concentrations Trial-in-Progress Abstract Details Ongoing…
-
5 months ago benzinga.com
Atossa Therapeutics Announces Acceptance Of (Z)-Endoxifen DMD Manuscript For Publication In Degenerative Neurological And Neuromuscular Disease
Review article accepted for publication in Degenerative Neurological and Neuromuscular Disease and builds on Atossa's previously published Duchenne Muscular Dystrophy (DMD) researchSEATTLE, May 20,…
5 months ago prnewswire.com
Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy
Review article accepted for publication in Degenerative Neurological and Neuromuscular Disease and builds on Atossa's previously published Duchenne Muscular Dystrophy (DMD) research SEATTLE, May 20,…
5 months ago seekingalpha.com
Atossa Therapeutics, Inc. (ATOS) Discusses Challenges in Breast Cancer Drug Development and Innovation in Clinical Research Transcript
Atossa Therapeutics, Inc. (ATOS) Discusses Challenges in Breast Cancer Drug Development and Innovation in Clinical Research Transcript
-
5 months ago benzinga.com
Atossa Therapeutics To Host Virtual KOL Event Focused On Evolving Clinical And Translational Data Supporting Development Of (Z)-Endoxifen As Potential Next-Gen Endocrine Therapy Backbone Across Multiple ER-Positive Breast Cancer Settings
Event to feature Dr. Laura Esserman, internationally recognized surgical oncologist, breast cancer expert, and founder and principal investigator of the I-SPY TrialsSEATTLE, May 14, 2026 /PRNewswire/…
5 months ago prnewswire.com
Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer
Event to feature Dr. Laura Esserman, internationally recognized surgical oncologist, breast cancer expert, and founder and principal investigator of the I-SPY Trials SEATTLE, May 14, 2026…
-
5 months ago benzinga.com
Atossa Therapeutics Q1 EPS $(1.11) Misses $(0.94) Estimate
Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(1.11) per share which missed the analyst consensus estimate of $(0.94) by 19.35 percent. This is a 344 percent decrease over losses of…
5 months ago prnewswire.com
Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
SEATTLE, May 8, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other…
6 months ago prnewswire.com
Atossa Therapeutics Announces Publication of KARISMA Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal Women
Peer-reviewed data support (Z)-endoxifen's (Endoxifen) potential as a differentiated breast cancer risk prevention candidate by marked reduction of mammographic breast density (MBD) Doses of both 1…
-
6 months ago benzinga.com
Atossa Therapeutics Announces FDA Rare Pediatric Disease Designation To (Z)-endoxifen For The Treatment Of McCune-Albright Syndrome In Females
RPD designation is granted to drug candidates intended to treat serious or life-threatening diseases that primarily affect individuals from birth to 18 years of age. Upon approval of a qualifying…
6 months ago prnewswire.com
Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome
Designation expands (Z)-endoxifen program into rare pediatric endocrine disorder and qualifies Atossa for a Priority Review Voucher award upon approval SEATTLE, May 4, 2026 /PRNewswire/ -- Atossa…
7 months ago prnewswire.com
Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update
SEATTLE, March 25, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other…
7 months ago defenseworld.net
Hyperfine (NASDAQ:HYPR) and Atossa Genetics (NASDAQ:ATOS) Critical Comparison
Hyperfine (NASDAQ: HYPR - Get Free Report) and Atossa Genetics (NASDAQ: ATOS - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two…
7 months ago globenewswire.com
The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology
VANCOUVER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) -- Equity-Insider. com News Commentary - Big money is moving back into biotech. Institutional investors have been writing some of the…
7 months ago prnewswire.com
Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives
Kathy Puyana Theall, M.D. and Adebola Giwa, M.D.
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
10 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
1 year ago benzinga.com
This Excelerate Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
This Excelerate Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
-
3 years ago benzinga.com
Earnings Scheduled For August 14, 2023
Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report quarterly loss at $0.23 per share on revenue of $6.88 million.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 258 companies hit new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 241 companies hit new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 167 companies set new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
Monday saw 825 companies set new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 1076 companies hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 340 stocks hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 215 companies set new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 540 companies set new 52-week lows.